 SAN DIEGO, May 21, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today announced that Janssen Pharmaceutica N.V. Janssen received two positive opinions from the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA recommending to broaden the existing marketing authorization for the DARZALEX daratumumab subcutaneous SC formulation, which uses ENHANZE technology, in two new indications. 